
    
      This study is a multicenter non randomized control study. Patients with decompensated liver
      cirrhosis are going to be assigned to receive standard medical care plus UC-MSC treatment
      with two different protocol (group 1 and group 2) or standard medical care (control). Four
      times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to
      the group 1ï¼ˆonce every 4 days), and two times of MSC infusion once every 7 days to the group
      2. The primary outcome is survival rates in one year. Secondary outcomes are liver function,
      liver ascites and MELD score.
    
  